New Mexico Cannabis: 1,050+ Licensed Retailers, 138% Capture, and the El Paso Effect
New Mexico peaked at $590 million in 2024 and is now declining. But the headline number obscures two separate stories: 61.9% flower price compression since launch, and a border export market that has grown 301% since launch and now accounts for nearly 20% of all state revenue.
Market Overview
New Mexico legalized adult-use cannabis under the Cannabis Regulation Act (HB 2) in June 2021. First recreational sales began April 1, 2022. The state chose an open-license model with no cap on operators — a deliberate policy decision to promote competition and price accessibility.
Key metrics:
- ~1,050 licensed retailers statewide per CCD's Cannabis Reporting Online Portal (CROP); active storefronts are a subset of licensed locations
- 2025 total sales: $567.4 million (NM CCD sales data)
- 2024 total sales: $590.3 million (peak year)
- $4.04/g flower (February 2025, BioTrack volume-weighted average; was $10.61/g at launch)
- 138% estimated resident capture at current pricing
- Regulated by the Cannabis Control Division (CCD) under the Regulation & Licensing Department
Flower Pricing
New Mexico's pricing data comes from the 2025 Supply & Demand Analysis prepared by Cannabis Public Policy Consulting (CPPC) using 85 million retail records from the state's BioTrack seed-to-sale system — the first comprehensive track-and-trace analysis since launch. The price compression in New Mexico is the most severe of any state in this dataset:
| Product | Apr 2022 | Feb 2025 | Decline |
|---|---|---|---|
| Flower | $10.61/g | $4.04/g | -61.9% |
| Pre-rolls | $10.38/g | $5.38/g | -48.2% |
| Vapes | $72.57/g | $18.68/g | -74.3% |
| Concentrates | $54.82/g | $12.43/g | -77.3% |
Flower fell from $10.61/g at launch to $4.04/g in 35 months — nearly identical to the retail price of Oregon's mature market after a decade of competition. The mechanism is straightforward: uncapped licenses with no supply constraints produced immediate oversaturation and commodity-speed price discovery.
| Market | Pre-tax Price | Tax Burden | Final Price | Legal Capture |
|---|---|---|---|---|
| Michigan | $2.96/g | ~17% | ~$3.46 | 165% |
| Colorado | $3.18/g | 15-20% | $3.66-3.82 | 104% |
| Oregon | $3.33/g | 17-20% | $3.89-4.00 | 100% |
| Massachusetts | $4.01/g | 17-20% | $4.69-4.81 | 100% |
| New Mexico | $4.04/g | ~20-21% | ~$4.80 | 138% |
| Montana | $5.34/g | 20-23% | $6.41-6.57 | 107% |
| Nevada | $5.11/g | ~27% | $6.49 | 100% |
| California | $6.11/g | 23-40% | $7.52-8.55 | 63% |
| Illinois | $6.25/g | 25-35% | $8.13 | 30% |
| New York | $10.61/g | 20-22% | $12.70 | 8% |
| Minnesota | $13.54/g | 22-25% | $16.50-16.90 | 6% |
At $4.80/g out the door, New Mexico has eliminated the price variable from the legal vs. illicit calculus for virtually every resident consumer.
Tax Structure
- 12% cannabis excise tax on adult-use retail sales (medical is exempt)
- ~7.5–8.9% gross receipts tax on all cannabis retail including medical
- Combined effective burden: ~20–21% adult-use
- Medical patients pay only the GRT — no excise
The excise rate increases by one percentage point annually beginning July 1, 2025, reaching 18% maximum in 2030. The medical exemption creates meaningful economics for high-frequency consumers, similar to Montana's structure.
Total Addressable Market
New Mexico's adult population is approximately 1.54 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:
- 1.54 million adults 21+
- 277,200 estimated regular consumers (18%)
- 101.2 million grams annual resident demand
- Resident TAM at $4.04/g: ~$408.8 million
Actual 2025 revenue of $567.4M against the $408.8M resident TAM implies 138% capture — the legal market is selling approximately 38% more than all resident demand can account for. That surplus has a specific zip code.
Revenue Trend
| Year | Total Revenue | YoY Change | Notes |
|---|---|---|---|
| 2022 | $358.8M | — | Apr–Dec only (9 months) |
| 2023 | $560.0M | +56.1% | First full year |
| 2024 | $590.3M | +5.4% | Peak |
| 2025 | $567.4M | -3.9% | Declining |
Price compression is now outpacing volume growth. Revenue is declining even as grams sold continue to increase — the textbook signature of an oversupplied market where price falls faster than volume grows.
The El Paso Effect
El Paso has 680,000 residents. Texas has no legal cannabis. Sunland Park, New Mexico sits 15 minutes across the state line.
| Year | Sunland Park Revenue | % of State | Las Cruces Avg/Mo |
|---|---|---|---|
| 2022 (9mo) | $14.6M | 4.1% | $3.2M |
| 2023 | $38.5M | 6.9% | $3.1M |
| 2024 | $56.5M | 9.6% | $3.1M |
| 2025 | $61.6M | 10.9% | $2.8M |
Sunland Park has grown 301% since launch. Las Cruces — ten times the population, 8 miles away, serving New Mexico residents — has declined 24% over the same period. The divergence is a direct capture-rate readout: as flower prices fell from $10.61 to $4.04/g, the value proposition for El Paso residents making a 15-minute drive improved continuously. Las Cruces serves residents whose per-capita demand is fixed; lower prices mean lower revenue per transaction with no new buyers to offset it.
The full Doña Ana County cluster — Sunland Park, Chaparral, Anthony, Santa Teresa, Las Cruces — generated $112M in 2025, 19.7% of state revenue. Southeast New Mexico's Permian Basin border tells the same story at smaller scale: Jal (pop. ~2,000) generated $8.2M in 2025 at $4,111 per capita, the highest in the state, driven by Midland-Odessa oilfield workers.
Strip out the Doña Ana County cluster's confirmed $112M — nearly all of which serves El Paso — and New Mexico's remaining revenue sits close to the resident TAM of $408.8M. The resident market has achieved full capture. The export market is the growth story.
Dispensary Density
| Market | Stores | Adults 21+ | Per 100K | Revenue/Store | Legal Capture |
|---|---|---|---|---|---|
| New Mexico | ~1,050 licensed | 1.54M | ~68.2 | ~$540K | 138% |
| Montana | 557 | 870K | 49.2 | $587K | 107% |
| Colorado | 900 | 4.5M | 20.0 | $2.15M | 104% |
| Massachusetts | 405 | 5.6M | 7.2 | $4.07M | 100% |
| Nevada | 103 | 2.46M | 4.2 | $8.05M | 100% |
| Illinois | 264 | 10.4M | 2.1 | $7.42M | 30% |
At approximately 68 licensed retailers per 100K — 3× Colorado, 16× Nevada — New Mexico has the highest dispensary density of any state even accounting for the fact that licensed locations include some that never opened or have since closed. Average revenue per licensed retailer runs approximately $540K annually, the lowest in this dataset and well below what most operators need to cover rent, labor, compliance, and debt service. The CPPC study was direct: the market is headed toward a consolidation correction. The uncapped license model achieved competitive pricing and broad consumer access; it is now entering the phase where the weakest operators exit.
Home Cultivation
New Mexico permits up to six plants per adult 21+ with no proximity restriction to licensed dispensaries. At $4.04/g retail, home cultivation economics require volume and time investment that the consumer market simply doesn't support. Revenue impact is negligible.
What the CHS Literature Missed
New Mexico's public health infrastructure has engaged with CHS more substantively than most states — and the internal tension in that engagement is instructive.
The New Mexico Department of Health's 2017 epidemiology report (Victoria F. Dirmyer, PhD, Epidemiology and Response Division) documented CHS-coded ED visits from 2010 to 2015 during the medical-only program era. The report found increasing presentations and noted explicitly: "Not all chronic users of cannabis will develop CHS." It recommended clinician education for better recognition — framing CHS as a diagnostic challenge requiring specialist awareness, not a mass-prevalence consumer warning.
The NMDOH Medical Cannabis Program's Medical Director, Dr. Gary French, incorporated that data into a 2024 provider education presentation that cites the 32.9% Habboushe prevalence figure. Dr. French presents this alongside a pathogenesis framework describing CHS as triggered by CB1 receptor downregulation from prolonged high-dose cannabis use, with genetic predisposition as a contributing factor. His predisposing factors slide states directly: "Not every cannabis user develops CHS."
A syndrome requiring prolonged high-dose exposure with genetic predisposition is structurally a subset condition. A 32.9% prevalence rate among frequent users is not a subset — it's a near-majority. The presentation does not resolve that tension.
Dr. French's own diagnostic criteria slide resolves it behaviorally. Among confirmed CHS patients in the literature, 96.8% experience resolution of symptoms after stopping cannabis use. Cessation is effectively the only treatment that works. This means confirmed CHS patients stop using cannabis — by definition.
Now apply that to scale. If 32.9% of New Mexico's estimated 277,200 regular consumers had CHS, approximately 91,000 would be episodically incapacitated and overwhelmingly likely to cease use. At the 96.8% cessation rate embedded in the diagnostic criteria, roughly 88,000 would be cycling out of the market annually. That volume loss — from the heaviest users — would be visible in 85 million tracked BioTrack transactions as demand destruction: falling per-consumer purchase frequency, declining cohort retention, shrinking total volume despite price drops that should be pulling new consumers in.
Instead the market shows 138% capture with volume growing continuously through 2024. The diagnostic criteria themselves generate the falsification test. New Mexico's consumption data fails to produce the predicted signal — consistent with what behavioral analysis shows about actual CHS prevalence among regular consumers.
The Bottom Line
New Mexico built the most price-competitive legal cannabis market in the country through uncapped licensing, achieved full resident capture, and developed a substantial permanent export market to Texas in the process. The $567M market is 39% larger than the resident TAM because Sunland Park is not serving Sunland Park.
The near-term trajectory is consolidation. At $564K average annual revenue per store with 1,006 operators, the market cannot sustain its current structure. When the correction runs its course, the surviving operators will have lower competition, higher per-store revenue, and a stable $4/g equilibrium serving both New Mexico residents and the permanent border market. The floor isn't where prices stop falling. It's where they find a market that keeps buying.
This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.